eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis

To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. O...

Full description

Saved in:
Bibliographic Details
Published inInflammatory bowel diseases Vol. 20; no. 12; pp. 2276 - 2285
Main Authors Pedersen, Natalia, Thielsen, Peter, Martinsen, Lars, Bennedsen, Mette, Haaber, Anne, Langholz, Ebbe, Végh, Zsuzsanna, Duricova, Dana, Jess, Tine, Bell, Sally, Burisch, Johan, Munkholm, Pia
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford University Press 01.12.2014
Subjects
Online AccessGet full text
ISSN1078-0998
1536-4844
1536-4844
DOI10.1097/MIB.0000000000000199

Cover

Abstract To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.ResultsA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.ConclusionsWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
AbstractList BackgroundTo individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.ResultsA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.ConclusionsWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course. Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1. A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12. Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
Background: To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course. Methods: Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constantcare.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI [< or =]1; FC = 0, and TIBS [< or =]1. Results: A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values ([< or =]1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12. Conclusions: Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.BACKGROUNDTo individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.METHODSProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.RESULTSA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.CONCLUSIONSWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course.MethodsProspective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza.constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI ≤1; FC = 0, and TIBS ≤1.ResultsA total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P < 0.001), mean FC (437 versus 195, P < 0.001), and mean TIBS (6.7 versus 2.4, P < 0.001). Based on TIBS values (≤1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12.ConclusionsWeb-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
Author Martinsen, Lars
Thielsen, Peter
Duricova, Dana
Bennedsen, Mette
Jess, Tine
Burisch, Johan
Haaber, Anne
Munkholm, Pia
Pedersen, Natalia
Bell, Sally
Langholz, Ebbe
Végh, Zsuzsanna
Author_xml – sequence: 1
  givenname: Natalia
  surname: Pedersen
  fullname: Pedersen, Natalia
  organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark
– sequence: 2
  givenname: Peter
  surname: Thielsen
  fullname: Thielsen, Peter
  organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark
– sequence: 3
  givenname: Lars
  surname: Martinsen
  fullname: Martinsen, Lars
  organization: †Department of Gastroenterology, Nykoebing Falster Hospital, Nykoebing Falster, Denmark
– sequence: 4
  givenname: Mette
  surname: Bennedsen
  fullname: Bennedsen, Mette
  organization: ‡Department of Gastroenterology, Nordsjaellands Hospital, Frederikssund, Denmark
– sequence: 5
  givenname: Anne
  surname: Haaber
  fullname: Haaber, Anne
  organization: §Department of Gastroenterology, Gentofte Hospital, Gentofte, Denmark
– sequence: 6
  givenname: Ebbe
  surname: Langholz
  fullname: Langholz, Ebbe
  organization: §Department of Gastroenterology, Gentofte Hospital, Gentofte, Denmark
– sequence: 7
  givenname: Zsuzsanna
  surname: Végh
  fullname: Végh, Zsuzsanna
  organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark
– sequence: 8
  givenname: Dana
  surname: Duricova
  fullname: Duricova, Dana
  organization: ‖IBD Clinical and Research Center, ISCARE a. s., Charles University, Prague, Czech Republic
– sequence: 9
  givenname: Tine
  surname: Jess
  fullname: Jess, Tine
  organization: ¶Department of Epidemiology Research, States Serum Institute, Copenhagen, Denmark
– sequence: 10
  givenname: Sally
  surname: Bell
  fullname: Bell, Sally
  organization: Department of Gastroenterology, St. Vincent's University Hospital, Melbourne, Australia
– sequence: 11
  givenname: Johan
  surname: Burisch
  fullname: Burisch, Johan
  organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark
– sequence: 12
  givenname: Pia
  surname: Munkholm
  fullname: Munkholm, Pia
  organization: Gastroenterology Unit, Herlev University Hospital, Copenhagen, Denmark
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25248002$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1q3DAUhU1IyV_zBqEIuunGiSRLlpVdO7TNQIYuMqFLoZGvMgqyNLXkQLPti1fJJFBm01wt7hF858DlHFf7IQaoqjOCzwmW4mIx_3KO_x0i5V51RHjT1qxjbL9oLLoaS9kdVscp3WNMy5MH1SHllHXle1T9gSvQPq8v0Tz07sH1k_buUWcXA4oWLSBprx9dALQcQecBQkbL9RinuzXS6Aa8rQcd9B306Ces6pVORd1EPz0nuIAWzvd1jvUQexh1BnTrzZNwD4Bm0bvs0vvqndU-wenLPqluv31dzq7q6x_f57PP17VhuMu1gE62DeFAOsGZ1EJYSgW3puWUWGkp76DphTWCECOtMaseSy6p0dS2DSfNSfVpm7sZ468JUlaDSwa81wHilBRpO8x4Kxv5BpTyhjHCcEE_7qD3cRpDOUQ1pJVCSklpoT68UNNqgF5tRjfo8bd6baIAl1vAjDGlEawyLj_3kEftvCJYPdWuSu1qt_ZiZjvm1_z_2C62tjht3ub4C375u4w
CitedBy_id crossref_primary_10_1007_s10620_018_5054_z
crossref_primary_10_1097_MOG_0000000000000647
crossref_primary_10_1080_00365521_2020_1735506
crossref_primary_10_1080_14712598_2021_1942833
crossref_primary_10_3390_jcm9092905
crossref_primary_10_1093_ecco_jcc_jjw059
crossref_primary_10_1007_s10620_015_3620_1
crossref_primary_10_1016_j_cgh_2016_09_011
crossref_primary_10_1097_MIB_0000000000001082
crossref_primary_10_5217_ir_2017_15_4_434
crossref_primary_10_1016_j_cct_2015_03_006
crossref_primary_10_1186_s13075_022_02809_7
crossref_primary_10_1097_MIB_0000000000001034
crossref_primary_10_1080_00365521_2021_1892176
crossref_primary_10_26442_00403660_2018_12_000001
crossref_primary_10_1007_s11901_018_0412_z
crossref_primary_10_1016_j_eii_2016_04_002
crossref_primary_10_1016_j_cgh_2015_10_035
crossref_primary_10_1111_jgh_13691
crossref_primary_10_1080_00365521_2022_2041083
crossref_primary_10_3748_wjg_v29_i7_1139
crossref_primary_10_1002_nur_22091
crossref_primary_10_12968_gasn_2022_20_6_30
crossref_primary_10_3748_wjg_v25_i40_6158
crossref_primary_10_2147_PPA_S383304
crossref_primary_10_3109_00365521_2015_1014407
crossref_primary_10_2147_PPA_S424024
crossref_primary_10_1080_00365521_2021_1966832
crossref_primary_10_1097_MIB_0000000000001026
crossref_primary_10_1177_20552076241261906
crossref_primary_10_1097_MPG_0000000000003053
crossref_primary_10_1038_s41598_023_46892_5
crossref_primary_10_1080_1744666X_2023_2292768
crossref_primary_10_1016_j_eii_2015_02_005
crossref_primary_10_2196_11761
crossref_primary_10_1002_hsr2_70186
crossref_primary_10_1016_j_imu_2022_100867
crossref_primary_10_1093_ecco_jcc_jjx169
crossref_primary_10_1111_imj_13677
crossref_primary_10_1016_j_cgh_2020_04_038
crossref_primary_10_2196_11602
crossref_primary_10_2196_14630
crossref_primary_10_1111_imj_15132
crossref_primary_10_1053_j_gastro_2022_01_024
crossref_primary_10_1186_s12913_022_08787_5
crossref_primary_10_1016_j_dld_2017_08_026
crossref_primary_10_1177_1357633X19849280
crossref_primary_10_1016_j_gastrohep_2024_502320
crossref_primary_10_2196_30291
crossref_primary_10_1186_s41687_021_00323_z
crossref_primary_10_3390_genes12101465
crossref_primary_10_5056_jnm15071
crossref_primary_10_1093_ibd_izy162
crossref_primary_10_1016_j_ijmedinf_2023_105249
crossref_primary_10_1080_17474124_2017_1256200
crossref_primary_10_2196_31102
crossref_primary_10_3390_jpm15040123
crossref_primary_10_1093_ecco_jcc_jjae093
crossref_primary_10_3748_wjg_v23_i18_3356
crossref_primary_10_5217_ir_2018_16_3_366
crossref_primary_10_1016_S0140_6736_17_31327_2
crossref_primary_10_1038_s41598_023_35332_z
crossref_primary_10_1093_ecco_jcc_jjy140
crossref_primary_10_5662_wjm_v13_i4_194
crossref_primary_10_1093_crocol_otaa002
crossref_primary_10_1097_MIB_0000000000000472
crossref_primary_10_1016_j_pec_2021_10_017
crossref_primary_10_1080_14712598_2019_1666101
crossref_primary_10_1080_00365521_2021_2015801
crossref_primary_10_1080_17474124_2016_1200464
crossref_primary_10_1111_jgh_14872
crossref_primary_10_17235_reed_2017_5143_2017
crossref_primary_10_1097_MIB_0000000000000676
Cites_doi 10.1016/j.crohns.2011.09.008
10.1002/ibd.21841
10.1111/j.1365-2036.2012.05107.x
10.1136/gut.2010.220160
10.1016/j.crohns.2007.11.002
10.1016/j.cgh.2006.10.025
10.1046/j.1365-2036.2003.01648.x
10.1136/gut.43.1.29
10.1002/ibd.22895
10.1053/j.gastro.2006.10.011
10.1111/j.1572-0241.2007.01212.x
10.1111/j.1365-2036.2009.04164.x
10.3748/wjg.v20.i2.509
10.1080/00365520310000654
10.1002/ibd.20189
10.4088/PCC.v09n0202
10.1016/S0895-4356(98)00108-5
10.1038/ajg.2012.419
10.1038/ajg.2011.58
10.1016/j.cgh.2009.04.004
10.1111/j.1365-2036.2009.04103.x
10.1038/ajg.2011.67
10.1186/1743-422X-10-43
10.1136/gut.2004.056358
10.1136/gut.2004.060103
10.1038/ajg.2011.296
10.1371/journal.pone.0080633
10.1111/j.1547-5069.2006.00116.x
10.1002/ibd.20986
10.1111/j.1365-2036.2006.02809.x
10.3109/00365529609004876
10.1111/apt.12043
10.1002/ibd.22917
10.1002/ibd.20580
10.1586/17474124.2.3.299
10.1097/MEG.0b013e32833944bf
10.1111/j.1572-0241.2003.07522.x
10.1016/j.crohns.2011.11.002
10.1111/j.1365-2036.2010.04575.x
10.1002/ibd.21570
10.1007/s10620-011-1877-6
10.1016/j.crohns.2014.01.028
10.1111/apt.12650
10.1111/j.1365-2036.2008.03865.x
10.1097/01.MIB.0000436277.13917.c4
10.1016/j.crohns.2009.11.011
10.1136/gutjnl-2011-300486
10.1111/j.1572-0241.2002.05872.x
10.1111/j.1572-0241.2001.04683.x
10.1111/j.1365-2036.2008.03688.x
10.1053/j.gastro.2007.05.051
10.1136/gut.2007.138248
ContentType Journal Article
Copyright Copyright © 2014 Crohn's & Colitis Foundation of America, Inc. 2014
Copyright © 2014 Crohn's & Colitis Foundation of America, Inc.
Copyright_xml – notice: Copyright © 2014 Crohn's & Colitis Foundation of America, Inc. 2014
– notice: Copyright © 2014 Crohn's & Colitis Foundation of America, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7T5
H94
DOI 10.1097/MIB.0000000000000199
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Immunology Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList ProQuest One Academic Middle East (New)
MEDLINE
AIDS and Cancer Research Abstracts
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1536-4844
EndPage 2285
ExternalDocumentID 25248002
10_1097_MIB_0000000000000199
10.1097/MIB.0000000000000199
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.Z2
0R~
1OC
3WU
48X
53G
5GY
5VS
5WD
66C
7O~
8-0
8UM
AAAXR
AABZA
AACZT
AAKAS
AAPQZ
AAPXW
AARHZ
AARTV
AAUAY
AAVAP
AAYEP
ABBUW
ABDFA
ABEJV
ABGNP
ABJNI
ABNHQ
ABOCM
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVJ
ABXVV
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACUTJ
ACWDW
ACWRI
ACXNZ
ACYHN
ADBBV
ADBIZ
ADGZP
ADIPN
ADQBN
ADRTK
ADVEK
ADZCM
AENEX
AETBJ
AFFZL
AFOFC
AFTRI
AFUWQ
AFXAL
AGINJ
AGQXC
AGUTN
AHMBA
AHMMS
AIJEX
AIZYK
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ATGXG
AWKKM
BAYMD
BCRHZ
BEYMZ
BOYCO
BTRTY
C45
CDBKE
CS3
DAKXR
DR2
DU5
E.X
E3Z
EBS
EJD
ENERS
EX3
F5P
FECEO
FL-
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H0~
HZ~
IN~
IX1
KBUDW
KOP
KSI
KSN
LAW
MHKGH
NNB
NOMLY
NOYVH
NVLIB
N~7
N~B
O9-
OAUYM
OCZFY
ODMLO
OIG
OJZSN
OPAEJ
OVD
OWPYF
P2P
PAFKI
PQQKQ
QRW
ROX
RUSNO
RX1
S4S
TEORI
V2E
WOW
XV2
YAYTL
YKOAZ
YXANX
ZFV
31~
4.4
7X7
8-1
88E
8F7
8FI
8FJ
AAJQQ
AAPGJ
AAUQX
AAWDT
AAYXX
ABUWG
ACFRR
ACVCV
ACXQS
ACZBC
ADMTO
ADNBA
AEMQT
AFBPY
AFFQV
AFKRA
AFYAG
AFZJQ
AGKRT
AGMDO
AHGBF
AHRYX
AJAOE
AJBYB
AJDVS
AJNCP
AJNYG
ALXQX
APJGH
AQDSO
AQKUS
AVNTJ
BENPR
CCPQU
CITATION
EIHJH
FYUFA
H13
HMCUK
IAO
IHR
ITC
JXSIZ
LH4
LW6
M1P
MBLQV
NU-
OBFPC
OCUKA
ORVUJ
PHGZM
PHGZT
PJZUB
PPXIY
PSQYO
PUEGO
ROL
TMA
UKHRP
W99
WOQ
Y6R
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
AGORE
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
7T5
H94
ID FETCH-LOGICAL-c408t-7e896315e187549a77f2275fc6521f9f258e3d7fc711c9fccbd09592ca2f63513
IEDL.DBID 7X7
ISSN 1078-0998
1536-4844
IngestDate Sun Sep 28 00:10:39 EDT 2025
Sun Sep 28 08:34:10 EDT 2025
Fri Sep 19 20:52:59 EDT 2025
Wed Feb 19 02:41:17 EST 2025
Wed Oct 01 04:56:46 EDT 2025
Thu Apr 24 23:07:04 EDT 2025
Sat Feb 08 08:13:08 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords mesalazine
ulcerative colitis
multimatrix system
inflammatory bowel disease
web-based management
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c408t-7e896315e187549a77f2275fc6521f9f258e3d7fc711c9fccbd09592ca2f63513
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 25248002
PQID 3169799922
PQPubID 996336
PageCount 10
ParticipantIDs proquest_miscellaneous_1680456939
proquest_miscellaneous_1625344140
proquest_journals_3169799922
pubmed_primary_25248002
crossref_citationtrail_10_1097_MIB_0000000000000199
crossref_primary_10_1097_MIB_0000000000000199
oup_primary_10_1097_MIB_0000000000000199
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20141201
2014-12-00
2014-Dec
PublicationDateYYYYMMDD 2014-12-01
PublicationDate_xml – month: 12
  year: 2014
  text: 20141201
  day: 01
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: England
– name: Baltimore
PublicationTitle Inflammatory bowel diseases
PublicationTitleAlternate Inflamm Bowel Dis
PublicationYear 2014
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Walmsley (R37-9-20141113) 1998; 43
Baars (R14-9-20141113) 2009; 30
Inokuchi (R58-9-20141113) 2014; 20
Langholz (R3-9-20141113) 1996; 31
(R48-9-20141113) 2010; 24
Shale (R31-9-20141113) 2003; 18
Higgins (R24-9-20141113) 2009; 29
Lopez San (R19-9-20141113) 2005; 97
Travis (R56-9-20141113) 2012; 61
Burisch (R43-9-20141113) 2014; 8
Burisch (R2-9-20141113) 2014; 20
Ford (R8-9-20141113) 2011; 106
Kamm (R26-9-20141113) 2008; 57
Kane (R9-9-20141113) 2011; 56
Ford (R7-9-20141113) 2011; 106
Ohm (R41-9-20141113) 2006; 38
Langholz (R1-9-20141113) 1999; 46
Lakatos (R18-9-20141113) 2010; 4
Kane (R49-9-20141113) 2012; 18
Lichtenstein (R6-9-20141113) 2011; 33
Munkholm (R10-9-20141113) 2010; 22
Jowett (R36-9-20141113) 2003; 38
Kane (R11-9-20141113) 2006; 23
Travis (R32-9-20141113) 2008; 2
Elkjaer (R34-9-20141113) 2010; 22
Ediger (R16-9-20141113) 2007; 102
Sewitch (R22-9-20141113) 2003; 98
Schoepfer (R52-9-20141113) 2009; 15
Irvine (R42-9-20141113) 1996; 91
Dignass (R46-9-20141113) 2009; 7
Marteau (R5-9-20141113) 2005; 54
Talley (R47-9-20141113) 2011; 106
Elkjaer (R12-9-20141113) 2010; 59
Hunot (R40-9-20141113) 2007; 9
Elkjaer (R38-9-20141113) 2010; 31
Higgins (R35-9-20141113) 2005; 54
Kamm (R25-9-20141113) 2007; 132
De (R51-9-20141113) 2012; 6
Kane (R23-9-20141113) 2002; 97
Burisch (R44-9-20141113) 2014; 61
Schoepfer (R53-9-20141113) 2012; 6
Pedersen (R33-9-20141113) 2012; 36
Lichtenstein (R29-9-20141113) 2008; 27
Kane (R13-9-20141113) 2001; 96
Gifford (R17-9-20141113) 2013; 108
Long (R21-9-20141113) 2012; 18
Solomon (R54-9-20141113) 2012; 35
Yi (R57-9-20141113) 2013; 10
Lichtenstein (R28-9-20141113) 2007; 5
DHaens (R50-9-20141113) 2012; 18
Delvincourt (R59-9-20141113) 2014; 39
Horne (R39-9-20141113) 2013; 8
Moshkovska (R20-9-20141113) 2011; 17
Schreiber (R30-9-20141113) 2008; 2
Froslie (R55-9-20141113) 2007; 133
Kamm (R27-9-20141113) 2009; 15
Ware (R45-9-20141113) 1998; 51
Cerveny (R15-9-20141113) 2007; 13
26111214 - Inflamm Bowel Dis. 2015 Aug;21(8):E15-6
26083615 - Inflamm Bowel Dis. 2015 Aug;21(8):E14-5
References_xml – volume: 6
  start-page: 412
  year: 2012
  ident: R53-9-20141113
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2011.09.008
– volume: 18
  start-page: 1026
  year: 2012
  ident: R49-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.21841
– volume: 35
  start-page: 1386
  year: 2012
  ident: R54-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2012.05107.x
– volume: 59
  start-page: 1652
  year: 2010
  ident: R12-9-20141113
  publication-title: Gut
  doi: 10.1136/gut.2010.220160
– volume: 2
  start-page: 24
  year: 2008
  ident: R32-9-20141113
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2007.11.002
– volume: 5
  start-page: 95
  year: 2007
  ident: R28-9-20141113
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2006.10.025
– volume: 18
  start-page: 191
  year: 2003
  ident: R31-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1046/j.1365-2036.2003.01648.x
– volume: 43
  start-page: 29
  year: 1998
  ident: R37-9-20141113
  publication-title: Gut
  doi: 10.1136/gut.43.1.29
– volume: 18
  start-page: 2099
  year: 2012
  ident: R21-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.22895
– volume: 132
  start-page: 66
  year: 2007
  ident: R25-9-20141113
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2006.10.011
– volume: 102
  start-page: 1417
  year: 2007
  ident: R16-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2007.01212.x
– volume: 31
  start-page: 323
  year: 2010
  ident: R38-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2009.04164.x
– volume: 20
  start-page: 509
  year: 2014
  ident: R58-9-20141113
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v20.i2.509
– volume: 38
  start-page: 164
  year: 2003
  ident: R36-9-20141113
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365520310000654
– volume: 13
  start-page: 1244
  year: 2007
  ident: R15-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.20189
– volume: 9
  start-page: 91
  year: 2007
  ident: R40-9-20141113
  publication-title: Prim Care Companion J Clin Psychiatry
  doi: 10.4088/PCC.v09n0202
– volume: 51
  start-page: 1167
  year: 1998
  ident: R45-9-20141113
  publication-title: J Clin Epidemiol
  doi: 10.1016/S0895-4356(98)00108-5
– volume: 108
  start-page: 249
  year: 2013
  ident: R17-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2012.419
– volume: 91
  start-page: 1571
  year: 1996
  ident: R42-9-20141113
  publication-title: Am J Gastroenterol
– volume: 106
  start-page: S2
  year: 2011
  ident: R47-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.58
– volume: 7
  start-page: 762
  year: 2009
  ident: R46-9-20141113
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2009.04.004
– volume: 30
  start-page: 864
  year: 2009
  ident: R14-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2009.04103.x
– volume: 106
  start-page: 601
  year: 2011
  ident: R8-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.67
– volume: 10
  start-page: 43
  year: 2013
  ident: R57-9-20141113
  publication-title: Virol J
  doi: 10.1186/1743-422X-10-43
– volume: 54
  start-page: 782
  year: 2005
  ident: R35-9-20141113
  publication-title: Gut
  doi: 10.1136/gut.2004.056358
– volume: 54
  start-page: 960
  year: 2005
  ident: R5-9-20141113
  publication-title: Gut
  doi: 10.1136/gut.2004.060103
– volume: 106
  start-page: 2070
  year: 2011
  ident: R7-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.296
– volume: 8
  start-page: e80633
  year: 2013
  ident: R39-9-20141113
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0080633
– volume: 22
  start-page: 695
  year: 2010
  ident: R34-9-20141113
  publication-title: Eur J Gastroenterol Hepatol
– volume: 38
  start-page: 292
  year: 2006
  ident: R41-9-20141113
  publication-title: J Nurs Scholarsh
  doi: 10.1111/j.1547-5069.2006.00116.x
– volume: 61
  start-page: B4778
  year: 2014
  ident: R44-9-20141113
– volume: 15
  start-page: 1851
  year: 2009
  ident: R52-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.20986
– volume: 23
  start-page: 577
  year: 2006
  ident: R11-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2006.02809.x
– volume: 31
  start-page: 260
  year: 1996
  ident: R3-9-20141113
  publication-title: Scand J Gastroenterol
  doi: 10.3109/00365529609004876
– volume: 36
  start-page: 840
  year: 2012
  ident: R33-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.12043
– volume: 18
  start-page: 2218
  year: 2012
  ident: R50-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.22917
– volume: 15
  start-page: 1
  year: 2009
  ident: R27-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.20580
– volume: 2
  start-page: 299
  year: 2008
  ident: R30-9-20141113
  publication-title: Expert Rev Gastroenterol Hepatol
  doi: 10.1586/17474124.2.3.299
– volume: 22
  start-page: 912
  year: 2010
  ident: R10-9-20141113
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0b013e32833944bf
– volume: 97
  start-page: 249
  year: 2005
  ident: R19-9-20141113
  publication-title: Rev Esp Enferm Dig
– volume: 98
  start-page: 1535
  year: 2003
  ident: R22-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2003.07522.x
– volume: 24
  start-page: 127
  year: 2010
  ident: R48-9-20141113
  publication-title: Mesalazine in inflammatory bowel disease: a trendy topic once again Can J Gastroenterol
– volume: 6
  start-page: 557
  year: 2012
  ident: R51-9-20141113
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2011.11.002
– volume: 33
  start-page: 672
  year: 2011
  ident: R6-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2010.04575.x
– volume: 17
  start-page: 1874
  year: 2011
  ident: R20-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1002/ibd.21570
– volume: 56
  start-page: 3463
  year: 2011
  ident: R9-9-20141113
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-011-1877-6
– volume: 8
  start-page: 1030
  year: 2014
  ident: R43-9-20141113
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2014.01.028
– volume: 39
  start-page: 712
  year: 2014
  ident: R59-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.12650
– volume: 29
  start-page: 247
  year: 2009
  ident: R24-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2008.03865.x
– volume: 20
  start-page: 36
  year: 2014
  ident: R2-9-20141113
  publication-title: Inflamm Bowel Dis
  doi: 10.1097/01.MIB.0000436277.13917.c4
– volume: 4
  start-page: 283
  year: 2010
  ident: R18-9-20141113
  publication-title: J Crohns Colitis
  doi: 10.1016/j.crohns.2009.11.011
– volume: 61
  start-page: 535
  year: 2012
  ident: R56-9-20141113
  publication-title: Gut
  doi: 10.1136/gutjnl-2011-300486
– volume: 97
  start-page: 1853
  year: 2002
  ident: R23-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2002.05872.x
– volume: 96
  start-page: 2929
  year: 2001
  ident: R13-9-20141113
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2001.04683.x
– volume: 27
  start-page: 1094
  year: 2008
  ident: R29-9-20141113
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2008.03688.x
– volume: 133
  start-page: 412
  year: 2007
  ident: R55-9-20141113
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2007.05.051
– volume: 46
  start-page: 400
  year: 1999
  ident: R1-9-20141113
  publication-title: Dan Med Bull
– volume: 57
  start-page: 893
  year: 2008
  ident: R26-9-20141113
  publication-title: Gut
  doi: 10.1136/gut.2007.138248
– reference: 26083615 - Inflamm Bowel Dis. 2015 Aug;21(8):E14-5
– reference: 26111214 - Inflamm Bowel Dis. 2015 Aug;21(8):E15-6
SSID ssj0020209
Score 2.4030962
Snippet To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease...
BackgroundTo individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term...
Background: To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2276
SubjectTerms Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Colitis, Ulcerative - drug therapy
Colitis, Ulcerative - psychology
Computer-Assisted Instruction
Drug Administration Schedule
Female
Follow-Up Studies
Health Knowledge, Attitudes, Practice
Humans
Inflammatory bowel disease
Internet
Male
Medication Adherence
Mesalamine - therapeutic use
Middle Aged
Patient Education as Topic
Precision Medicine
Prognosis
Prospective Studies
Quality of Life
Recurrence
Self Care
Severity of Illness Index
Telemedicine
Young Adult
Title eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis
URI https://www.ncbi.nlm.nih.gov/pubmed/25248002
https://www.proquest.com/docview/3169799922
https://www.proquest.com/docview/1625344140
https://www.proquest.com/docview/1680456939
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1536-4844
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0020209
  issn: 1078-0998
  databaseCode: 7X7
  dateStart: 19960201
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1536-4844
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0020209
  issn: 1078-0998
  databaseCode: BENPR
  dateStart: 19960201
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1078-0998
  databaseCode: DR2
  dateStart: 19950101
  customDbUrl:
  isFulltext: true
  eissn: 1536-4844
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0020209
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS-QwFA6rwuKL6O6q440s7MO-BJs0aRpfxCu6UBF3hp230kkTGCit2vEX-Mc9adIZdEHtW-lpG3pOer5zR-iXBpshSiJFEiYN4SbhpAALjETCKG0NE2XX7Dm7Sa5G_M9YjIPDrQ1plf0_sftRl412PvLDmCYuAqUYO75_IG5qlIuuhhEaS2iFAlRxUi3HC4Mr8ikeYOG4EL9K-9I5JQ-z61PfurA_fPfXhWp6Ve72H-rstM_lOloLsBGfeD5voC-m_oa-ZiEw_h09G19PdISv5xVWocISNxZnpi2qrpE0HvaZ5XjoR_TgAv81lSU-j7XE_8yEON1W4t5lhqc1zqZVSWYNcZNzXHcJPKq08V3D8VmXQ9f-QKPLi-HZFQnzFQhwKJ0RaVLYflQYCkYLV4WUljEprE5Ap1tlmUhNXEqrJaVaWa0npfMaMl0wCziFxptouW5qs42wVFayGIgiG3N4SDGhqRZJKhLLhWBigOL-0-Y6NB93MzCqvA-CA0PytwwZIDK_69433_iA_jdw7ZOkez1r87Br23whYwP0c34Z9psLohS1aZ7anILBGAOG5NF7NKlDyiqG12x5sZkvignGHUjfeX8Bu2gVoBn3iTN7aHn2-GT2Af7MJgedjB-gldOLm9s7ODu_Yy_0EvzR
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9QwDLfGkIAXxH8OBgQJJF6itWnSNEgIwWC6Y-teuBP3VnppIk2q2m29adoz32efcU7T3AmQBi_ra900ip3Yju2fAd5o9BmiNFI0ZdJQblJOS_TAaCSM0tYwUfVgz_lBOp7xb3Mx34CLUAvj0irDmdgf1FWr3R35dhKnLgKlGPt4dExd1ygXXQ0tNLxY7JnzM3TZug-TL8jft4ztfp3ujOnQVYDivLIllSZDoYuFidFU56qU0jImhdUpajKrLBOZSSpptYxjrazWi8rdlTFdMovaOU5w3BtwkycRd1j9cr528CKfUoIelUspUFko1VNyO5989lCJ4fFos2tV-Ft53V9Wbq_tdu_B3cFMJZ-8XN2HDdM8gFv5EIh_CL-Mr196Tyariq6hopO0luSmK-seuJpMQyY7mfqWQKQk301tqc-brcgPs6BOl1YkXNGRw4bkh3VFly11nXocmgWZ1dp4lHKy0-fsdY9gdi0r_xg2m7YxT4FIZSVLkCiyCcdBykWcaZFmIrVcCCZGkISlLfQAdu56btRFCLojQ4o_GTICuvrqyIN9_IP-HXLtP0m3AmuL4ZToirVMj-D16jXubxe0KRvTnnZFjA5qgjYrj66iyZxlrhL8zRMvNqtJMcG4cwqeXT2BV3B7PM33i_3Jwd5zuINmIfdJO1uwuTw5NS_Q9FouXvbyTuDndW-wS9U4Nik
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=eHealth&rft.jtitle=Inflammatory+bowel+diseases&rft.au=Pedersen%2C+Natalia&rft.au=Thielsen%2C+Peter&rft.au=Martinsen%2C+Lars&rft.au=Bennedsen%2C+Mette&rft.date=2014-12-01&rft.issn=1078-0998&rft.volume=20&rft.issue=12&rft.spage=2276&rft.epage=2285&rft_id=info:doi/10.1097%2FMIB.0000000000000199&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_MIB_0000000000000199
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0998&client=summon